<DOC>
	<DOC>NCT02928406</DOC>
	<brief_summary>This multicenter study will assess the safety of atezolizumab as second-line treatment for participants with locally advanced or metastatic urothelial or non-urothelial cancer of the urinary tract in addition to evaluate the efficacy of atezolizumab and potential tumor biomarkers associated with atezolizumab.</brief_summary>
	<brief_title>A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract</brief_title>
	<detailed_description />
	<mesh_term>Urologic Neoplasms</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Participants with histologically documented locally advanced (tumor (T) 4b, any node (N); or any T, N 23) or metastatic (M1, Stage IV) urothelial or nonurothelial carcinoma of the urinary tract Participants with measurable and nonmeasurable disease according to RECIST v1.1 Must have received one prior combination chemotherapy regimen for inoperable, locally advanced or metastatic urothelial or nonurothelial carcinoma of the urinary tract Representative formalinfixed paraffinembedded (FFPE) tumor specimen block Eastern cooperative oncology group (ECOG) performance status 0, 1 or 2 Treatment with more than one prior line of systemic therapy for inoperable, locally advanced or metastatic urothelial or nonurothelial carcinoma of the urinary tract Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 4 weeks prior to study treatment initiation Evidence of significant uncontrolled concomitant disease that could affect compliance with the protocol Significant renal disorder requiring dialysis or indication for renal transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>